Shots:

• The EU approval is based on the US FDA approval, Tavneos has been approved in combination with a rituximab or cyclophosphamide regimen for active GPA or MPA
• The therapy is expected to be available in H1’22 & will receive marketing authorization in all member states of the EU, Iceland, Liechtenstein & Norway. The therapy has received ODD from the US FDA & EMA for ANCA-associated vasculitis & C3G & is being studied in C3G, HS & LN
• ChemoCentryx gets all rights for Tavneos to treat orphan and renal diseases in the US, upon the Kidney Health Alliance & is eligible to receive royalties from Vifor on Ex-US sales, Vifor retains the rights to commercialize avacopan globally

Ref: ChemoCentryx | Image: SVB Leerink